Some mornings are better than others and Tuesday January 18th was definitely one of the really good ones as I woke up to a beautiful sunrise and the news that Roche has decided to do another Phase II trial with Tominersen. The decision is based upon the analyses made from data collected in the Generation…
Read more
ZOOM WEBINAR: Monday January 24th , 6 pm Central European time After several months digging into all the information collected in the Generation HD1 trial Roche is ready tell us about their findings in a webinar organized by EHA in collaboration with Roche and EHDN. Lauren Boak, PhD and Peter McColgan, MD, PhD from Roche…
Read more
Our voice on behalf of people with neurological diseases (ND) has been heard! EU has decided to include ND on the list of health care priorities. This paves the way for a better future also for Huntington patients. For many years the public health priorities have primarily been focusing on cancer, cardiovascular and diabetes. The…
Read more
1st of October the Healthe-rnd consortium was finally able to meet again face-to-face in Prague. Most of the partners were able to attend despite the ongoing restrictions due to the pandemic. The ones who couldn’t make it to Prague attended on Zoom. It was great to see each other again and also meet new faces as…
Read more
EHDN Online Plenary Meeting 2021 – Having listened to the presentations about ongoing and upcoming clinical trials during the EHDN virtual conference has filled me with renewed enthusiasm and energy – Says Astri Arnesen, EHA President . We were all hit by the setbacks in Roche and Waves trials earlier this year. But during the…
Read more
An article by by Prof Åsa Petersèn and Sanaz Gabery This article is modified and translated from Lund University homepage, Agata Garpenlind. Our results demonstrate that parts of the brain that manage emotions, the so-called limbic system, is affected early in HD mutation carriers. These changes may contribute to the development of psychiatric and cognitive symptoms. …
Read more
Tomsk, July 10, 2021 The European Huntington Association is happy to announce the launch of the international project «Moving Forward» in Russia! The first city to present the project was Tomsk, which is situated in Syberia. 17 members of the HD families and several doctors-neurologists attended the interregional “School of Health”, organized by the center…
Read more
Results from Generation HD1 As you all remember in March the independent Data Monitoring Committee advised Roche to halt dosing of the drug Tominersen. On April 27 Scott Schobel, Medical Director & Clinical Science Leader at Roche shared the interim analyses of the results from the Generation HD1 at the CHDI therapeutics conference. Drug effect…
Read more
30. March 2021. Yesterday, Wave Life Sciences gave an update on PRECISION-HD1 and PRECISION-HD2. Due to disappointing results, the biotechnology company has decided to stop the two Huntington’s disease trials. However, they will continue the development of a third drug candidate. The decision to stop the PRECISION-HD trials is not related to the stopped dosing of Tominersen…
Read more
In this first webinar of Speak About It, Jeanne Gravfort will talk about her own method: Free Your Mind. Learn more about how talking about challenges can help you cope with Huntington’s disease. Later on, you will have the opportunity to register for a course to learn more about the approach. WEBINAR:In this first webinar the 3rd of February you will get an introduction to Free Your Mind. In this webinar you will learn more about how talking…
Read more
